EyePoint Pharmaceuticals, Inc. ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für EyePoint Pharmaceuticals, Inc. zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um EyePoint Pharmaceuticals, Inc. zu Deinem Portfolio hinzuzufügen.
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in acco...
WATERTOWN, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in...
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q4 2023 Earnings Conference Call March 7, 2024 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Tessa Romero - JPMorgan Tyler Van Buren - TD Cowen Yatin Suneja - Guggenheim Jennifer Kim - Cantor Fitzgerald Graig Suvannavejh - Mizuho Securitie...
– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H 2024 –
WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 7, 2024 to report its fourth quarter and full-year 2023 financial r...
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.